Results 81 to 90 of about 3,177,071 (215)

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Exploring Psychedelic-Assisted Therapy and Sex Therapy Through the Lens of Optimal Sex and Attachment: A Potential for Transformative Healing

, 2022
Psychedelic-assisted therapy and sex therapy are two fringe disciplines within psychology that have yet to be merged. However, psychedelic-assisted therapy is showing promising results in healing underlying issues related to sexual concerns such as ...
Bain, Kristina
core  

The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial

Addiction, EarlyView.
Abstract Background and aims Ketamine assisted psychotherapy is a promising new treatment for alcohol use disorder (AUD). The psychoactive effects of repeated intravenous (IV) ketamine infusions in people with AUD and their mechanistic role in treating AUD are largely unknown.
Cassie Bloy, Ananya Sarma, Bethan Marsh, Lorna Hardy, Meryem Grabski, Merve Mollaahmetoglu, Joshua Shotton, Shamhethan Bhaskaran, Anne Lingford‐Hughes, H. Val Curran, Celia Morgan, Will Lawn   +11 more
wiley   +1 more source

Adolescent Psychedelic-Assisted Therapy

Acta Psychedelica
Amidst a growing prevalence of adolescent mental ill-health, there is a pressing need to develop effective therapeutic interventions. Despite promising results from adult trials of psychedelic-assisted therapies (P-AT), translating these interventions to adolescents presents challenges.
Bryony Insua-Summerhays, Edward Jacobs
openaire   +1 more source

Psychedelic‐assisted therapy for functional neurological disorders: A theoretical framework and review of prior reports

Pharmacology Research & Perspectives, 2020
Functional neurological disorders (FNDs), which are sometimes also referred to as psychogenic neurological disorders or conversion disorder, are common disabling neuropsychiatric disorders with limited treatment options. FNDs can present with sensory and/
Benjamin Stewart, Jon G. Dean, Adriana Koek, Jason Chua, Rafael Wabl, Kayla Martin, Naveed Davoodian, Christopher Becker, Mai Himedan, Amanda Kim, Roger Albin, Kelvin L. Chou, Vikas Kotagal   +12 more
doaj   +1 more source

Unlocking ‘stuckness’ and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic‐assisted therapy for substance use and mental health problems

Addiction, EarlyView.
Abstract Background and aims Australia recently down‐scheduled and authorised psychedelic‐assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness.
Sarah J. Catchlove, Katrin Oliver, Michael Savic, Shalini Arunogiri   +3 more
wiley   +1 more source

How Psychedelic-Assisted Treatment Works in the Bayesian Brain

Frontiers in Psychiatry, 2022
Psychedelics are experiencing a renaissance in clinical research. In recent years, an increasing number of studies on psychedelic-assisted treatment have been conducted. So far, the results are promising, suggesting that this new (or rather, rediscovered)
Daniel Villiger, Daniel Villiger
doaj   +1 more source

Ensuring Access to Psychedelic-Assisted Therapy in Rural Communities. [PDF]

Psychedelic Med (New Rochelle)
With several classical psychedelics being designated as breakthrough therapies and the recent review of a New Drug Application for 3,4-Methylenedioxymethamphetamine in the treatment of posttraumatic stress disorder, the likelihood of psychedelic medication becoming approved for clinical use in the United States is high.
Dhaliwal OM, Bobak L, Barnett BS.
europepmc   +3 more sources

Psychological change processes in alcohol use disorder: A qualitative study of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) with cognitive behavioural therapy

Addiction, EarlyView.
Abstract Background and aims This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT; BPL‐003) administered alongside psychological
Mathieu Seynaeve, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, James J. Rucker, Anthony Cleare, John Marsden   +6 more
wiley   +1 more source

Patient-therapist relationship in psychedelic-assisted therapy: Implications for future real-world settings.

General Hospital Psychiatry
The view that the use of serotonergic psychedelics in mental health care should always be psychotherapeutically embedded has recently been questioned. One argument against this model concerns the high costs it entails, which could limit the accessibility
Daniel Villiger
semanticscholar   +1 more source